Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

NCT05739188 | Unknown Phase 1

• 1 other identifier: BG-CT-22-012
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 2

Brief Summary

It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM).

Conditions

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory

Keywords

CAR-T; GPRC5D

Outcome Measures

Primary Outcomes (2)

• Incidence of adverse events(AE) after infusion

  The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.

  Up to 12 months after infusion

• Dose limited toxicity (DLT)

  Dose limited toxicity(DLT) was defined as the occurrence of any of the following adverse events within 28 days of the infusion of CAR-T cells after optimal supportive treatment, which were discussed with the investigator and determined to be associated or likely to be associated with the infusion.

  Up to 1 month after infusion

Secondary Outcomes (4)

• Overall Response Rate (ORR)

  Up to 2 years after infusion

• Concentration of CAR-T cells

  Days 4, 7, 10, 14 and months 2, 3, 6, 9, 12 after infusion

• Progression-free survival(PFS)

  Up to 2 years

• Overall survival(OS)

  Up to 2 years

Study Arms (1)

Anti-GPRC5D CAR-T

EXPERIMENTAL

Subjects who meet the enrollment conditions will receive intravenous infusion of anti--GPRC5D CAR-T Cells after lymphodepleting therapy.

Biological: Anti-GPRC5D CAR-T cells infusion

Interventions

Anti-GPRC5D CAR-T cells infusion BIOLOGICAL

This is a"3+3"dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%.

Anti-GPRC5D CAR-T

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient or his/her guardian understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure;
• Age 18-75 years old, gender unlimited;
• Patients diagnosed with multiple myeloma according to International Myeloma Working Group(IMWG) diagnostic criteria;
• Subjects who had failed treatment with at least 3 drugs of different mechanisms (including chemotherapy, proteasome inhibitors, immunomodulators, etc.), or had progressed or relapsed during the last treatment period or within 6 months after the end of treatment;
• The presence of measurable lesions at screening was determined according to any of the following criteria, defined as: (1) serum monoclonal immunoglobulin (M-protein) level ≥1.0 g/dL; (2) urine M protein level ≥200 mg/ 24h; (3) Light chain multiple myeloma diagnosed with no measurable lesion in serum or urine: serum immunoglobulin free light chain ≥10 mg/dL and serum immunoglobulin κ/γ free light chain ratio abnormal;
• The patient has recovered from the toxicity of the prior treatment, i.e., CTCAE toxicity grade \< 2 (unless the abnormality is related to the tumor or is stable as judged by the investigator and has little impact on safety or efficacy);
• Eastern cooperative oncology group (ECOG) score is 0-2;
• Survival is expected to be greater than 3 months;
• Adequate liver , kidney and cardiopulmonary function;
• Willingness to complete the informed consent process and to comply with study procedures and visit schedule.

You may not qualify if:

• Have been diagnosed with or treated for aggressive malignancies other than multiple myeloma;
• Prior antitumor therapy (prior to blood collection for CAR-T preparation) : targeted therapy, epigenetic therapy, or investigational drug therapy within 14 days or at least 5 half-lives, whichever is shorter;
• It is suspected that MM has involved the central nervous system or meninges and has been confirmed by MRI or CT, or there are other active central nervous system diseases;
• Clinically significant central nervous system diseases, such as epilepsy, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, psychosis, active central nervous system involvement or cancerous meningitis;
• HBsAg or HBcAb are positive, and the quantitative detection of hepatitis B virus(HBV) DNA in peripheral blood is more than 100 copies / L;hepatitis C virus (HCV) antibody and HCV RNA in peripheral blood are positive; HIV antibody positive; Syphilis antibody is positive in the first screening;
• Pregnant or breastfeeding;
• Severe active viral, bacterial or uncontrolled systemic fungal infections; Hereditary bleeding / coagulation diseases, history of non traumatic bleeding or thromboembolism, other diseases that may increase the risk of bleeding, etc;Patients who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks before screening, or who plan to undergo ASCT during the study period;
• Any unstable systemic disease: including but not limited to unstable angina, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure \[New York Heart Association (NYHA) classification ≥ grade III\], severe arrhythmia with poor drug control, liver, kidney or metabolic diseases;
• Had hypersensitivity or intolerance to any drug used in this study;
• Persons with serious mental illness;
• Alcoholics or persons with a history of drug abuse;
• Systemic diseases judged by researchers to be unstable: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
• Patients with acute/chronic graft-versus-host disease (GVHD) or requiring immunosuppressive therapy for GVHD within 6 months prior to screening;
• Any unsuitable to participate in this trial judged by the investigator.

Sponsors & Collaborators

• 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China: lead

Study Sites (2)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Kunming, Yunnan, 650100 P.R.China, China

RECRUITING

No.212 Daguan Road, Xishan District

Kunming, Yunnan, China

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Sanbin Wang, MD

  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sanbin Wang, MD

CONTACT

13187424131; Sanbin1011@163.com

Sanbin Wang, MD

CONTACT

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a"3+3"dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%.

Study Record Dates

• First Submitted: February 4, 2023
• First Posted: February 22, 2023
• Study Start: February 7, 2023
• Primary Completion: February 1, 2025
• Study Completion: December 31, 2025
• Last Updated: February 23, 2023

Record last verified: 2023-02

Locations

CN (2)